Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 20/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 19/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521464 | 1.00 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5829159 | 0.91 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5828816 | 0.90 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5828179 | 0.90 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5828611 | 0.89 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5828678 | 0.88 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5828819 | 0.87 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL10405623 | 0.86 | WEE1 (0.76) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5829205 | 0.86 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 | |
| SCHEMBL5828870 | 0.86 | WEE1 (1.00) | WEE1CHEK1PRKCQDAPK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | claimed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | claimed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | claimed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | claimed |
| US-12551584-B1 | Lewis Y radioimmunotherapy for the treatment of cancer | ACTINIUM PHARMACEUTICALS, INC. | 2026-02-17 | — | — | US | disclosed |
| US-20250339571-A1 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | ACTINIUM PHARMACEUTICALS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447218-B1 | Radioconjugates directed to MHC-complexed antigens in cancer | ACTINIUM PHARMACEUTICALS, INC. | 2025-10-21 | — | — | US | disclosed |
| US-20250205375-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20240390532-A1 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | ACTINIUM PHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4408486-A1 | RADIOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-3027774-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | Memorial Sloan Kettering Cancer Center (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| US-20160022720-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES ASSOCIATED WITH ACTIVATED T CELLS AND/OR B CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| WO-2015017863-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-02-05 | — | — | WO | disclosed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447218-B1 | Radioconjugates directed to MHC-complexed antigens in cancer | CD74, IL2RA, FCGR2A | WEE1 2789/4885CHEK1 2356/4885PRKCQ 1815/4885 |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CDC7, CDC16, MCM7 | WEE1 46/4885CHEK1 92/4885PRKCQ 3509/4885 |
| US-20250339571-A1 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | CD47, PTDSS1, PTDSS2 | WEE1 1466/4885CHEK1 382/4885PRKCQ 1547/4885 |
| US-20160022720-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES ASSOCIATED WITH ACTIVATED T CELLS AND/OR B CELLS | TP53, NFATC1, ACIN1 | WEE1 713/4885CHEK1 66/4885PRKCQ 304/4885 |
| US-12551584-B1 | Lewis Y radioimmunotherapy for the treatment of cancer | CD47, CD274, LY96 | WEE1 1332/4885CHEK1 59/4885PRKCQ 1802/4885 |
| US-20240390532-A1 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | HSP90B1, HSPA5, HSPB1 | WEE1 1879/4885CHEK1 852/4885PRKCQ 1761/4885 |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | DCK, TK1, DTYMK | WEE1 132/4885CHEK1 7/4885PRKCQ 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.